ENO2 and adenocarcinoma: The extreme elevations of markers for adenocarcinoma (CEA, CA19‐9), neuroendocrine tumours (NSE, ProGRP), squamous carcinoma (CYFRA, SCC), and hepato‐pancreato‐biliary cancer (PIVKA‐II, DUPAN‐2) naturally raised the differential diagnosis of synchronous primary cancers.